-
How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low
Wednesday, September 6, 2023 - 6:37pm | 596President Joe Biden’s Inflation Reduction Act, which allows Medicare to negotiate the price of some prescription drugs, remains the talk of the town as investors sell off shares in pharmaceutical companies such as Pfizer Inc. (NYSE: PFE) because drugs associated with the companies...
-
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth
Wednesday, August 9, 2023 - 10:03am | 515Shares of Eli Lilly And Co (NYSE: LLY) Tuesday spiked, after the company reported strong second-quarter results. The results came amid an exciting earnings season. Here are some key analyst takeaways from the earnings release. Cantor Fitzgerald On Eli Lilly Analyst Louise Chen maintained an...
-
Pfizer's Late-Stage COVID-19 Vaccine Data In Adolescents Reinforces Bull Case, Analyst Says
Wednesday, March 31, 2021 - 10:29am | 354Pfizer Inc. (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) announced positive results Wednesday from a late-stage study of the COVID-19 vaccine BNT162b2 in adolescents. The Pfizer Analyst: Cantor Fitzgerald analyst Louise Chen maintained an Overweight rating on Pfizer with a $...
-
Pfizer-BioNTech Plan Vaccine Emergency Use Filing Within Days After Final Analysis Confirm Efficacy, Safety
Wednesday, November 18, 2020 - 9:20am | 643Pfizer Inc. (NYSE: PFE) andBioNTech SE – ADR (NASDAQ: BNTX) have managed to stay ahead in the vaccine race by a hair's breadth. Within days after Moderna Inc (NASDAQ: MRNA) released its first interim analysis, the U.S.-German combo announced results from the final analysis of their...
-
A Pfizer Analyst's 3 Possible Coronavirus Vaccine Readout Scenarios
Monday, November 2, 2020 - 5:22pm | 456The first Interim data from an ongoing, late-stage coronavirus trial by Pfizer Inc. (NYSE: PFE) is expected sometime after the U.S. presidential elections, according to an analyst at Cantor Fitzgerald. The Pfizer Analyst: Louise Chen has an Overweight rating and $53 price target for Pfizer...
-
Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward
Tuesday, August 4, 2020 - 2:10pm | 519Amarin Corporation plc (NASDAQ: AMRN) shares were advancing strongly Tuesday following the release Tuesday of second-quarter results. What Happened: Amarin reported second-quarter revenue of $135.3 million, up 34% year-over-year, but below the $149.48-million consensus estimate. "...
-
Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential
Wednesday, July 29, 2020 - 11:30am | 1009Pfizer Inc. (NYSE: PFE) reported forecast-beating second-quarter results Tuesday and raised its full-year guidance. The beat-and-raise quarter — and an update on its coronavirus vaccine program — sent the biopharma's shares higher by 3.94%. The Pfizer Analysts: BofA Securities...
-
4 Takeaways On Pfizer's Latest Coronavirus Data
Monday, July 20, 2020 - 2:46pm | 447The data shows more positives about Pfizer’s (NYSE: PFE) coronavirus vaccine candidate and remains in-line with its German partner BioNTech’s (NASDAQ: BNTX) study, according to Cantor Fitzgerald Securities. The Pfizer Analyst: Louise Chen maintained an Overweight rating on...
-
Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'
Wednesday, June 17, 2020 - 11:52am | 715Amarin Corporation plc (NASDAQ: AMRN) announced late Tuesday a settlement agreement with Apotex for resolving a patent lawsuit regarding a generic version of Amarin's drug Vascepa. The Amarin Analysts: Cantor Fitzgerald analyst Louise Chen reaffirmed an Overweight rating and $35 price...
-
Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals
Monday, June 1, 2020 - 2:25pm | 530Pfizer Inc. (NYSE: PFE) shares declinded Monday after the company said that a Phase 3 breast cancer treatment study — known as "PALLAS" — is unlikely to hit the primary goal, citing efficacy and futility analysis done by an Independent Data Monitoring...
-
Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development
Tuesday, May 26, 2020 - 10:48am | 745Merck & Co., Inc. (NYSE: MRK) announced a trio of initiatives Tuesday to combat the coronavirus pandemic. The Kenilworth, New Jersey-based, large-cap biopharma announced two partnerships: one to develop an antiviral treatment and another to develop a vaccine. In a third deal,...
-
Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut
Wednesday, April 29, 2020 - 11:04am | 474Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance. The Merck Analysts Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107 price target. SVB Leerink analyst Daina Graybosch...
-
Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment
Tuesday, March 31, 2020 - 10:53am | 772Amarin Corporation plc (NASDAQ: AMRN) shares were tumbling Tuesday in reaction to a negative verdict issued by a U.S. District Court regarding generic versions of its fish oil pill Vascepa. Amarin shares, which rose to 52-week high of $26.12 in mid-December in reaction to a Vascepa...
-
Merck To Spin Off Slow-Growing Women's Health, Legacy, Biosimilars Businesses: What You Need To Know
Wednesday, February 5, 2020 - 1:16pm | 677Pharma giant Merck & Co., Inc. (NYSE: MRK) announced Wednesdaythat it plans to splinter into two companies in a bid to pursue aggressive growth. Separately, the company reported largely positive fourth-quarter results and issued robust guidance for the full year 2020. A ‘Lean And Mean...
-
After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target
Monday, December 16, 2019 - 10:37am | 591Christmas came early for Amarin Corporation plc (NASDAQ: AMRN) with the FDA's approval of an expanded label for its fish oil pill Vascepa ahead of a scheduled Dec. 28 decision date. The label expansion approved Friday includes the indication of cardiovascular risk reduction in...